Zantac Efferdose
This article was originally published in The Tan Sheet
Executive Summary
Warner-Lambert receives FDA approval March 8 for an efficacy supplement to NDA 20-745 for the labeled indication "For the prevention of heartburn, acid indigestion and sour stomach brought on by consuming food and beverages." The effervescent tablet (ranitidine 75 mg) was cleared Feb. 26, 1998 for heartburn treatment ("The Tan Sheet" March 2, 1998, p. 1). The launch of the product is still pending. Warner-Lambert may have been awaiting approval of the prevention indication before introducing the line extension to Zantac 75
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning